2؉ -sensing protein of the EF-hand family that is expressed predominantly in cardiac muscle, plays a pivotal role in cardiac contractility in vitro and in vivo. It has recently been demonstrated that by restoring Ca 2؉ homeostasis, S100A1 was able to rescue contractile dysfunction in failing rat hearts. Myocardial contractility is regulated not only by Ca 2؉ homeostasis but also by energy metabolism, in particular the production of ATP. Here, we report a novel interaction of S100A1 with mitochondrial F 1 -ATPase, which affects F 1 -ATPase activity and cellular ATP production. In particular, cardiomyocytes that overexpress S100A1 exhibited a higher ATP content than control cells, whereas knockdown of S100A1 expression decreased ATP levels. In pull-down experiments, we identified the ␣-and ␤-chain of F 1 -ATPase to interact with S100A1 in a Ca 2؉ -dependent manner. The interaction was confirmed by colocalization studies of S100A1 and F 1 -ATPase and the analysis of the S100A1-F 1 -ATPase complex by gel filtration chromatography. The functional impact of this association is highlighted by an S100A1-mediated increase of F 1 -ATPase activity. Consistently, ATP synthase activity is reduced in cardiomyocytes from S100A1 knockout mice. Our data indicate that S100A1 might play a key role in cardiac energy metabolism. S100 proteins are a family of soluble, EF-hand Ca 2ϩ -binding proteins which exhibit a remarkable cell-and tissue-specific expression pattern. They are involved in numerous intracellular activities, such as cell proliferation and differentiation, or the dynamics of cytoskeletal constituents (reviewed in references 4, 9, and 30). The most abundant S100 protein in the heart is S100A1 (12; reviewed in reference 4). It has been recognized recently as a positive inotropic intracellular regulator of cardiac as well as skeletal muscle Ca 2ϩ homeostasis and contractility (15, 16, 18, 19, 20) . Accordingly, S100A1-deficient mice exhibited an impaired cardiac contractility response to hemodynamic stress (5). Notably, the absence of S100A1 significantly accelerates the development of contractile dysfunction after myocardial infarction, with a rapid onset of cardiac remodeling and a transition to heart failure combined with excessive mortality (21). Normal contractile function and Ca 2ϩ homeostasis, on the other hand, could be restored in failing myocardium in postinfarcted rat hearts by S100A1 gene delivery (19).
S100A1, a Ca
2؉ -sensing protein of the EF-hand family that is expressed predominantly in cardiac muscle, plays a pivotal role in cardiac contractility in vitro and in vivo. It has recently been demonstrated that by restoring Ca 2؉ homeostasis, S100A1 was able to rescue contractile dysfunction in failing rat hearts. Myocardial contractility is regulated not only by Ca 2؉ homeostasis but also by energy metabolism, in particular the production of ATP. Here, we report a novel interaction of S100A1 with mitochondrial F 1 -ATPase, which affects F 1 -ATPase activity and cellular ATP production. In particular, cardiomyocytes that overexpress S100A1 exhibited a higher ATP content than control cells, whereas knockdown of S100A1 expression decreased ATP levels. In pull-down experiments, we identified the ␣-and ␤-chain of F 1 -ATPase to interact with S100A1 in a Ca 2؉ -dependent manner. The interaction was confirmed by colocalization studies of S100A1 and F 1 -ATPase and the analysis of the S100A1-F 1 -ATPase complex by gel filtration chromatography. The functional impact of this association is highlighted by an S100A1-mediated increase of F 1 -ATPase activity. Consistently, ATP synthase activity is reduced in cardiomyocytes from S100A1 knockout mice. Our data indicate that S100A1 might play a key role in cardiac energy metabolism. S100 proteins are a family of soluble, EF-hand Ca 2ϩ -binding proteins which exhibit a remarkable cell-and tissue-specific expression pattern. They are involved in numerous intracellular activities, such as cell proliferation and differentiation, or the dynamics of cytoskeletal constituents (reviewed in references 4, 9, and 30). The most abundant S100 protein in the heart is S100A1 (12; reviewed in reference 4). It has been recognized recently as a positive inotropic intracellular regulator of cardiac as well as skeletal muscle Ca 2ϩ homeostasis and contractility (15, 16, 18, 19, 20) . Accordingly, S100A1-deficient mice exhibited an impaired cardiac contractility response to hemodynamic stress (5) . Notably, the absence of S100A1 significantly accelerates the development of contractile dysfunction after myocardial infarction, with a rapid onset of cardiac remodeling and a transition to heart failure combined with excessive mortality (21) . Normal contractile function and Ca 2ϩ homeostasis, on the other hand, could be restored in failing myocardium in postinfarcted rat hearts by S100A1 gene delivery (19) .
In addition to Ca 2ϩ homeostasis, myocardial workload depends on cardiac metabolism. As the energy demand changes, the flux through the mitochondrial ATP synthase (F 1 F oATPase), which is responsible for the bulk of ATP synthesis in the myocardium, must change so that ATP synthesis matches ATP consumption (reviewed in references 6 and 10). To sustain cardiac function in all possible situations, there has to be a strict correlation between energy production, energy transfer, and energy utilization (reviewed in reference 29) . In this regard, Ca 2ϩ has emerged as a major factor for adapting mitochondrial ATP production to the constantly varying energy demand of the cell. Consistently, several studies provided evidence that F 1 F o -ATPase-dependent ATP synthesis correlates with Ca 2ϩ levels in heart cells (reviewed in reference 1). Furthermore, metabolic pathway abnormalities that result in an imbalance of several metabolic reactions, for example, a decreased phosphocreatine/ATP ratio, indicative of an increase in ADP, an alteration of oxidative phosphorylation, and a decreased ATP/ADP ratio, lead to abnormal contraction and relaxation and eventually result in the failing of the heart. Thus, it is conceivable that energy starvation may contribute to heart failure (reviewed in reference 11).
Because S100A1 is able to restore a reduced phosphocreatine/ATP ratio and Ca 2ϩ homeostasis in failing cardiomyocytes (19), we examined whether S100A1 has an influence on cardiac energy homeostasis in neonatal rat ventricular cardiomyocytes (NVCMs) . Here, we demonstrate a Ca 2ϩ -dependent interaction of S100A1 with the ␣-and ␤-chain of the F 1 -ATPase in NVCMs and isolated mitochondria. Moreover, this interaction is consolidated by colocalization in immunofluorescence and immunoelectron microscopy studies and the isolation of an S100A1-F 1 -ATPase complex by gel filtration chromatography. Furthermore, the physiological significance of S100A1 in energy metabolism is validated through the effects of S100A1 overexpression and knock-down on ATP production in NVCMs and its influence on F 1 -ATPase activity.
Based on the data presented, a new role for S100A1 in cardiac energy metabolism emerges.
MATERIALS AND METHODS
Reagents. ATP (disodium salt), phosphoenolpyruvate, NADH, pyruvate kinase, lactate dehydrogenase, and isoproterenol were purchased from Sigma.
Generation of an S100A1 adenovirus. The generation of an S100A1 adenovirus (AdS100A1) by the pAdTrack-CMV/pAdEasy-1 system has been described elsewhere (15) . To facilitate the identification of infected cells, AdS100A1 carried the green fluorescent protein (GFP) reporter gene in addition to the human S100A1 cDNA (GenBank accession number X58079). Each transgene was independently expressed under the control of a cytomegalovirus promoter sequence. To rule out the possibility that the infection procedure itself had an effect on the amount of S100A1 in the cell, cells were infected with the corresponding adenovirus carrying GFP cDNA alone as a control (Adcontrol).
Isolation and primary culture of NVCMs and adult mice. Ventricular cardiomyocytes from 1-to 2-day-old neonatal hearts (NVCMs) were isolated as described in detail elsewhere (17) . NVCMs were cultured in Dulbecco's modified Eagle's medium supplemented with penicillin-streptomycin (100 units/ml), Lglutamine (2 mM), and 1% fetal calf serum (FCS Gold; PAA Laboratories GmbH) at 37°C in a 95% air-5% CO 2 humidified atmosphere for 2 to 3 days. Adenoviral infection of NVCMs was carried out in serum-free M199 medium with a multiplicity of infection of 8 PFU per cell. After 4 h of incubation at 37°C, M199 medium was changed to Dulbecco's modified Eagle's medium supplemented with penicillin-streptomycin (100 units/ml), L-glutamine (2 mM), and 1% fetal calf serum. The efficiency of adenoviral gene transfer was monitored 24 h later by GFP fluorescence. Accordingly, approximately 95% of NVCMs were infected. S100A1-deficient (SKO) mice have previously been described (5). Adult ventricular cardiomyocytes from C57BL/6 wild-type (WT) and SKO mice (2 to 3 months of age) were enzymatically isolated using a pressure-and temperaturecontrolled retrograde coronary perfusion protocol as reported elsewhere (24) . Subsequently, WT and SKO cardiomyocytes were pelleted and sonicated in ice-cold EGTA-buffered sonication solution (20 mM HEPES, 1.0 MgCl 2 , 2.0 mM EGTA, pH 7.2) with a free [Ca 2ϩ ] of 0.2 mM. Samples were kept on ice until measurements. Free [Ca 2ϩ ] was calculated by applying the program REACT. S100A1 RNA interference. Custom-designed synthetic S100A1 small interfering RNA (siRNA) and scrambled siRNA as a negative control were purchased from Eurogentec. S100A1 siRNA is target-specific 20-to 25-nucleotide siRNA to knock down the gene expression of S100A1 in NVCMs (sense, 5Ј-UGG AGA CCC UCA UCA AUG UdTdT-3Ј; antisense, 5Ј-ACA UUG AUG AGG GUC UCC AdTdT-3Ј). NVCMs were transfected with S100A1 and control siRNA oligonucleotides (100 nM) by using Effectene transfection reagent according to the manufacturer's instructions (QIAGEN). After incubation at 37°C for 24 h, cells were lysed and subjected to Western blotting.
Indirect immunofluorescence. Immunofluoresence labeling of NVCMs was carried out as previously described (17) . Freshly isolated NVCMs were cultured for 2 days on glass coverslips and incubated with the fluorescent dye MitoTracker Red (1 M; Molecular Probes) for 30 min. Cells were fixed, permeabilized, and labeled with a monoclonal anti-S100A1 antibody (diluted 1:200; Sigma) and a polyclonal F 1 -ATPase antibody (diluted 1:400). The latter was a kind gift from Pfanner (Institute for Biochemistry and Molecular Biology, Freiburg, Germany). The secondary antibodies used were Alexa Fluor 488-conjugated anti-mouse immunoglobulin (diluted 1:800; Alexis) and Cy5-conjugated anti-rabbit immunoglobulin (diluted 1:400; Jackson ImmunoResearch Lab). Confocal images were obtained using a 100ϫ oil objective lens on a Leica TCS SP laser scanning confocal microscope. Digitized confocal images were processed by Leica software and Adobe Photoshop.
Immunoelectron microscopy. Isolated mitochondria and pieces of heart tissue from 3-day-old neonatal rats were fixed as previously described (25) . Ultrathin sections were cut and mounted on carbon-Parlodion-coated copper grids. Specimens were blocked with 2% bovine serum albumin (BSA) in phosphate-buffered saline (PBS) two times for 5 min prior to incubation with S100A1 antibody (diluted 1:100; Sigma) for 2 h at room temperature (RT). Grids were washed in PBS, blocked in 2% BSA in PBS two times for 5 min, and then incubated with 10 nm gold-conjugated goat anti-mouse secondary antibody (BBInternational) for 1 h at RT.
For double immunolabeling, sections were sequentially incubated with the primary antibodies and the corresponding gold-conjugated secondary antibody (10 nm and 5 nm, respectively) for 2 h at RT. After being washed in PBS and water, grids were stained with a mixture of 6% uranyl acetate for 1 h, rinsed with water, and then poststained for 2 min with lead citrate. Electron micrographs were recorded on a Hitachi 7000 at 80 kV.
Isolation of mitochondria. Mitochondria were isolated from the hearts of adult male rats by differential centrifugation steps as described previously (3) . Briefly, minced heart tissue was homogenized with approximately 10 ml/g tissue homogenization buffer (0.1 M KCl, 0.05 M MOPS [morpholinepropanesulfonic acid], 5 mM MgSO 4 , 1 mM EDTA, 1 mM ATP, 0.2% BSA, pH 7.4), using a Teflon glass homogenizer with a loose-fitting piston. The homogenate was centrifuged at 300 ϫ g at 4°C for 10 min. The supernatant was poured through a double-layered cheese cloth and centrifuged again at 5,000 ϫ g at 4°C for 10 min. Pelleted mitochondria were resuspended in 1 ml homogenization buffer and centrifuged again at 5,000 ϫ g at 4°C for 10 min. The pellet was resuspended in 0.15 ml KME buffer (0.1 M KCl, 0.05 M MOPS, 0.5 mM EGTA, pH 7.4). The protein concentration in the mitochondrial suspension was determined by the Bradford method (Sigma), using bovine albumin fraction V as a standard.
Purification of F 1 -ATPase/S100A1-F 1 -ATPase complex and F 1 -ATPase activity. Purification of the bovine F 1 -ATPase was carried out as previously described (22) . The S100A1-F 1 -ATPase complex was prepared as follows. Purified F 1 -ATPase (15 mg), stored as an ammonium sulfate precipitate, was collected by centrifugation (16,000 ϫ g), redissolved in complex buffer (20 mM Tris, pH 7.4, 100 mM NaCl, 1 mM MgCl 2 , 2 mM CaCl 2 ), and desalted on a Micro Bio-Spin column (Amersham Pharmacia Biotech). The enzyme was then mixed with a 12.5-fold molar excess of S100A1 over F 1 -ATPase and incubated for 30 min at 37°C. MgATP (1 mM) was added at 1 and 15 min to yield a final concentration of 2 mM. ATPase activity was measured at 37°C with an ATP-regenerating system as reported by following the oxidation of NADH to NAD ϩ at 340 nm in a Hewlett-Packard spectrophotometer (2) . The assay was carried out in 1 ml assay buffer (50 mM Tris, pH 7.4, 50 mM KCl, 2 mM MgCl 2 ) containing 2 mM ATP, 2 mM phosphoenolpyruvate, 0.4 mM NADH, 12.5 U pyruvate kinase, and 12.5 U lactate dehydrogenase. The reaction was started by adding 10 l of F 1 -ATPase or the S100A1-F 1 -ATPase complex in the presence of 2 mM or 0.2 mM CaCl 2 . The decline of NADH absorbance at 340 nm allows for monitoring of the rate of ATP hydrolysis (optical density/min).
Determination of mitochondrial ATP synthase activity. The enzymatic activity of the mitochondrial ATP synthase complex was measured using a spectrophotometric assay as described elsewhere with minor modifactions (7) . Briefly, aliquots of cardiomyocyte homogenates from adult WT and SKO mice were added to EGTA-buffered activity solution (in mM: 60 sucrose, 50 triethanolamine-HCl, 50 KCl, 4 MgCl 2 , 2 ATP, 1.5 phosphoenolpyruvate, 2 EGTA, 1 KCN, 0.001 thapsigargin, pH 7.4, with KOH) supplemented with 200 M NADH, 5 U pyruvate kinase, and 5 U lactate dehydrogenase. Thapsigargin was used to block the activity of the Ca 2ϩ -sensitive sarcoplasmic reticulum Ca 2ϩ
ATPase. Free [Ca 2ϩ ] was adjusted to either 0.2 M or 0.2 mM, determined by the program REACT. The conversion of NADH to NAD ϩ was followed spectrophotometrically at 340 nm at 37°C for 3 min. Recombinant human S100A1 protein was added 10 min prior to measurement as indicated. Oligomycin (10 g/ml) was used to block the mitochondrial ATP synthase. Mitochondrial ATP synthase activity was calculated as the difference between total and oligomycininsensitive conversion of NADH to NAD ϩ . Gel filtration chromatography. Upon its preparation as described above, the S100A1-F 1 -ATPase complex was chromatographed at RT at a flow rate of 0.3 ml/min on a HiLoad Superdex 200 column that was preequilibrated in complex buffer. The absorbance of the eluant was monitored at 280 nm. Individual fractions (0.3 ml) were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
Measurement of ATP production. The ATP content of NVCMs was determined by the luciferin-luciferase system according to the manufacturer's protocol (ATP bioluminescence assay kit HS II; Roche).
Recombinant proteins. A human S100A1 cDNA (accession number X58079) was subcloned into the expression vector pGEX-6P1 containing glutathione S-transferase (GST) cDNA. S100A1 was produced as a fusion protein with a 26-kDa GST at the NH 2 terminus (GST-S100A1) by an isopropyl-␤-D-thiogalactopyranoside (IPTG)-driven expression system in Escherichia coli. The fusion protein was purified using glutathione-Sepharose 4B (Amersham Pharmacia Biotech) and dialyzed against PBS.
The GST fusion constructs of palpha3 and pbeta1 were generated by PCR overlap extension using cDNAs of the ␣-and ␤-chain of mitochondrial bovine heart F 1 -ATPase (palpha3 and pbeta1). The two external primers for the palpha3 construct used were as follows: 5Ј EcoRI primer, 5Ј-GAATTCCAGAAA CCGGCACT, and 3Ј XhoI primer, 5Ј-CTCGAGAGCTTC AAATCCAGC. The PCR product was digested with EcoRI and XhoI and inserted into the pGEX-4366 BOERRIES ET AL. MOL. CELL. BIOL.
6P1 vector at the corresponding restriction sites. For the GST-pbeta1 expression construct, the two external primers were as follows: 5Ј SalI primer, 5Ј-CGGTC GACTCATGGCCGCTCAAGCATCTCC, and 3Ј NotI primer, 3Ј-CCCGCCG GCCGCTCATGAGTGCTCTTCAGCCAAC. The PCR product was digested with SalI and NotI and inserted into the pGEX-6P1 vector at the respective sites. GST fusion proteins of the ␣-chain and ␤-chain of F 1 -ATPase were expressed and purified as described for GST-S100A1. A recombinant human S100A1 cDNA (accession number X58079) was also subcloned into the expression vector pHis-TRX-1 containing a thrombin cleavage side. S100A1 was produced as a fusion protein with a histidine tag at the NH 2 terminus by an IPTG-driven expression system in E. coli. The fusion protein was purified using a HiTrap chelating HP column (Amersham Pharmacia Biotech) according to the manufacturer's protocol. Subsequently, the histidine tag was removed by thrombin cleavage and purified S100A1 was dialyzed against 25 mM Tris, pH 7.45.
GST pull-down assays. GST fusion proteins (0.02 mg/ml GST-S100A1, GST-␣-F 1 -ATPase, and GST-␤-F 1 -ATPase) or GST alone was bound to glutathione S-Sepharose slurries in an incubation buffer (IB2; 100 mM NaCl, 20 mM Tris, pH 7.4, 0.05% Triton X-100, containing 2 mM CaCl 2 , 0.2 mM CaCl 2 , or 2 mM EGTA) for 1.5 h at 4°C. Isolated neonatal rat cardiomyocytes (5 ϫ 10 6 cells) and 1 mg/ml isolated heart mitochondria were homogenized in a homogenization buffer (100 mM NaCl, 20 mM Tris, pH 7.4, 1 mM MgCl 2 , 1 mM phenylmethylsulfonyl fluoride, 1 l DNase, 0.2% Triton X-100, supplemented with a Complete mini EDTA-free protease inhibitor tablet; Roche) containing 2 mM CaCl 2 , 0.2 mM CaCl 2 , or 2 mM EGTA. Homogenates of neonatal cardiomyocytes, isolated mitochondria, and recombinant S100A1 (1 M) were incubated with GST-S100A1, GST-␣-F 1 -ATPase, GST-␤-F 1 -ATPase, or GST slurries for 2.5 h at 4°C. Incubation of purified F 1 -ATPase with GST-S100A1 or GST slurries was carried out at RT for 1 h. Mixtures were washed six times with IB2, applied to spin columns, and centrifuged at 400 ϫ g for 1 min. The columns were spin washed twice with IB2. Unbound protein was removed by spin wash steps for 3 min at 2,300 ϫ g. Bound proteins were eluted with SDS-PAGE sample buffer (5% SDS) and analyzed by SDS-PAGE and mass spectrometry.
Mass spectrometry analysis. For mass spectrometry, gel slices were excised from silver-stained SDS-PAGE gels and digested with 0.25 g trypsin (Promega) in 50 mM ammonium bicarbonate (pH 8.0) at 37°C for 16 h. The resulting peptides were analyzed by capillary liquid chromatography/tandem mass spectrometry (MS/MS), using a Magic C 18 100-m by 10-cm high-performance liquid chromatography column (Spectronex) connected to a Finnigan TSQ7000 tandem mass spectrometer (ThermoFinnigan). A linear gradient from 2 to 75% buffer B (0.1% acetic acid and 80% [vol/vol] acetonitrile in water) in buffer A (0.1% acetic acid in water) was generated with a Rheos 2000 high-pressure liquid chromatography system (Flux) at 100 l/min. A precolumn flow splitter reduced the flow to approximately 500 nl/min. The eluting peptides were ionized by electrospray ionization and detected, and the peptides were automatically selected and fragmented by collision-induced dissociation (MS/MS). Individual MS/MS spectra were searched in the data bank using Mascot software (http://www.matrixscience .com).
Western blotting. To reveal the presence of S100A1 in the SDS-PAGE-separated protein mixtures of pull-down experiments, standard Western blotting using a specific polyclonal anti-S100A1 antibody (SA 5632, diluted 1:10,000; Eurogentec) was performed. Blots were developed with the Avidix chemiluminescence detection system (Tropix; Applied Biosystems). To detect the presence of S100A1 on the SDS-PAGE-separated protein mixtures of siRNA experiments, standard Western blotting using an epitope affinity-purified anti-S100A1 antibody (SP5355P, diluted 1:5,000; Acris) was performed (19) . Proteins were visualized with a LI-COR infrared imager (Odyssey), and quantitative densitometric analysis was performed by applying Odyssey version 1.2 infrared imaging software. Signals were normalized to calsequestrin densitometric levels that were not different between groups.
Statistical analyses. Data are presented as means Ϯ standard errors of the means (SEM). An unpaired Student t test and a two-way repeated analysis of variance were performed to test for differences between groups. A P value of Ͻ0.01 was accepted as statistically significant.
RESULTS
S100A1 enhances ATP production in neonatal rat cardiomyocytes. To examine the effects of an increased S100A1 protein level on ATP production in NVCMs, cells were transduced by means of an adenoviral construct that independently drives the expression of human S100A1 and GFP (AdS100A1). As a control, NVCMs were infected with the corresponding adenovirus carrying only GFP cDNA (Adcontrol). At 24 hours postinfection, AdS100A1, Adcontrol, and nontransfected (NT) cells were processed for ATP quantification by using a luciferase-based luminometry reaction. Under resting conditions (without electrical stimulation), the amount of ATP was raised by ϳ67% in AdS100A1 cells compared to that in control cells expressing endogenous S100A1 only (Fig. 1) . In response to electrical stimulation at 1 Hz, ATP production was increased by ϳ110% in cells overexpressing S100A1. These data suggest that S100A1 is involved in the regulation of energy metabolism in NVCMs.
Calcium-dependent interaction of S100A1 with mitochondrial proteins. To identify possible target proteins of S100A1 implicated in the ATP increase observed in S100A1-overexpressing cells, we performed GST-S100A1 pull-down assays with different heart homogenates in the presence of 2 mM CaCl 2 or 2 mM EGTA (Fig. 2) . Silver-stained protein bands that were specific to GST-S100A1 pull-down assays in the presence of 2 mM CaCl 2 were analyzed by mass spectrometry. In homogenates of isolated NVCMs ( Fig. 2A) , five different mitochondrial proteins, hydroxyl-coenzyme A dehydrogenase, the ␣-chain of F 1 -ATPase, isocitrate dehydrogenase 2, annexin V, and adenine nucleotide translocase, were identified as potential binding partners of S100A1. The corresponding proteins were also pulled down from adult rat heart homogenates (data not shown).
To substantiate the finding that S100A1 interacts with a number of mitochondrial proteins, we isolated mitochondria from adult rat hearts and prepared corresponding mitochondrial extracts for pull-down assays with GST-S100A1 (Fig. 2B) . Analyses by mass spectrometry revealed that the S100A1-interacting proteins identified in isolated mitochondria were the same as those detected in isolated NVCMs. In addition, the ␤-chain of F 1 -ATPase (2a) was identified in mitochondrial extracts. S100A1 colocalizes with F 1 -ATPase in mitochondria. We used immunofluorescence and immunoelectron microscopy to probe the cellular distribution of S100A1 and its association with F 1 -ATPase in situ. Indirect immunofluorescence labeling of NVCMs with an S100A1 antibody revealed a punctate distribution of S100A1 (green) throughout the cytoplasm ( Fig. 3A and D ) and, to a lesser extent, in the nucleus. Because NVCMs were incubated in parallel with
MitoTracker Red, mitochondria (red) could be identified as "bullet-shaped" structures (Fig. 3B) . Merging the two confocal images revealed a partial colocalization of S100A1 with mitochondria (yellow) (Fig. 3C) .
To analyze the interaction of S100A1 and F 1 -ATPase at the subcellular level, we performed double immunolabeling experiments with NVCMs with a monoclonal antibody against S100A1 and a polyclonal antibody that reacts with all five subunits of F 1 -ATPase. As illustrated in Fig. 3E , the F 1 -ATPase antibody typically revealed bullet-shaped structures (blue), which were similar to the mitochondria stained by MitoTracker. Merging the respective confocal images (Fig. 3D and E) clearly showed that S100A1 partially localized to the same confocal volume as F 1 -ATPase (turquoise) (Fig. 3F) .
To obtain more-detailed information on this colocalization, we used double immunogold labeling of S100A1 and F 1 -ATPase on ultrathin sections of a 3-day-old neonatal rat heart. As indicated by the red circles in the electron micrograph displayed in Fig. 3G , we observed numerous cases in which 10-nm gold particles (S100A1) and 5-nm gold particles (F 1 -ATPase) appeared in close proximity. With the dimensions of the two antibody complexes being taken into account, a spacing of approximately 30 nm between 10-nm and 5-nm gold particles is indicative of a physical interaction between the two binding sites. In conclusion, these immunolocalization studies substantiated the localization of S100A1 in mitochondria and its direct interaction with F 1 -ATPase.
The interaction of S100A1 with the ␣-and ␤-chain of F 1 -ATPase depends on calcium and pH. To confirm the direct interaction of S100A1 with the ␣-and ␤-chain of F 1 -ATPase, we performed reverse pull-down assays. For this purpose, recombinant GST-␣-chain and GST-␤-chain fusion proteins or GST alone was coupled to glutathione-Sepharose beads in the presence of 2 mM CaCl 2 , 0.2 mM CaCl 2 , or 2 mM EGTA and subsequently incubated with recombinant S100A1 protein.
FIG. 2.
Results of GST-S100A1 pull-down assays with different homogenates. Protein eluates from different GST-S100A1 pull-down assays were separated on denaturing SDS-polyacrylamide gels and individual proteins identified by mass spectrometry. (A) Five mitochondrial proteins from a homogenate of NVCMs that interact with GST-S100A1 were identified: hydroxyl-coenzyme A dehydrogenase (1), the ␣-chain of F 1 -ATPase (2), isocitrate dehydrogenase 2 (3), annexin V (4), and adenine nucleotide translocase (5). (B) Similar proteins were pulled down from isolated mitochondria by GST-S100A1 in the presence of 2 mM CaCl 2 . In addition, the ␤-chain of F 1 -ATPase (2a) and the hydroxyacyl dehydrogenase (6) were identified. The band representing GST-S100A1 is indicated by an arrowhead. Bound protein was eluted and analyzed by SDS-PAGE and Western blotting using an S100A1 antibody (Fig. 4A ).
In the presence of 2 mM CaCl 2 and 0.2 mM CaCl 2 , the GST-␣-chain and the GST-␤-chain fusion protein pulled down two bands with apparent molecular masses of 10 and 20 kDa, respectively, which were recognized by the S100A1 antibody. The migration behavior of these two bands corresponds to that of the monomeric and dimeric forms of recombinant S100A1. Both bands were absent when pull-down assays were carried out in the presence of EGTA or GST control beads.
Furthermore, when GST-S100A1 pull-down assays with purified bovine heart F 1 -ATPase were performed under different pH conditions, a pH-sensitive interaction was observed ( Fig.  4B and C) . At pH 7.4, the ␣-and ␤-chain of F 1 -ATPase were pulled down by GST-S100A1 in the presence of 2 mM CaCl 2 . However, in the presence of 2 mM EGTA, the two respective bands were significantly diminished. When the pH was lowered to 6.8, the binding of F 1 -ATPase to GST-S100A1 was barely detectable even in the presence of 2 mM CaCl 2 . In control pull-down assays carried out in the presence of 2 mM EGTA or immobilized GST alone, no bands were visible (data not shown). These data confirmed that at pH 7.4, there is a direct interaction between S100A1 and the ␣-and ␤-chain of F 1 -ATPase in the presence of 2 mM or 0.2 mM CaCl 2 .
S100A1 forms a complex with F 1 -ATPase and increases its activity.
To analyze the interaction of S100A1 and F 1 -ATPase in molecular detail, we isolated the S100A1-F 1 -ATPase complex by gel filtration chromatography. For complex formation, purified F 1 -ATPase was incubated at pH 7.4 with a 12.5-fold molar excess of S100A1 in the presence of 2 mM CaCl 2 or 2 mM EGTA for 30 min at 37°C. To maintain F 1 -ATPase activity, 1 mM MgATP was added to the mixture at 1 and 15 min. After incubation, the mixture was subjected to gel filtration chromatography on a Superdex 200 HiLoad column and individual fractions were analyzed by SDS-PAGE. In the presence of CaCl 2 , two prominent peaks were identified in the elution profile (Fig. 5A) . Based on the apparent molecular masses of the proteins that eluted in the first peak (fractions 36 to 42), this peak contained the five subunits of F 1 -ATPase (␣-, ␤-, ␥-, ␦-, and ε-chain) and, as suggested by their electrophoretic mobility, monomeric and dimeric S100A1 (10-and 20-kDa bands, respectively) (Fig. 5A) . The presence of S100A1 was confirmed by Western blotting using an S100A1-specific antibody and by mass spectrometry (data not shown). The elution profile of peak I also displayed a small shoulder (fractions 40 to 42) that possibly represents aggregation products of S100A1 and F 1 -ATPase subunits. SDS-PAGE of the second, smaller peak (fractions 50 to 54) contained predominantly free S100A1 monomers and dimmers and only traces of F 1 -ATPase subunits.
In the presence of 2 mM EGTA, gel filtration chromatography of the S100A1-F 1 -ATPase complex (Fig. 5B) produced   FIG. 4 . Results of pull-down assays indicate an interaction between S100A1 and F 1 -ATPase. (A) Western blot of eluates of GST-F 1 -ATPase ␣-and ␤-chain pull-down assays performed with recombinant human S100A1 in the presence of 2 mM CaCl 2 , 0.2 mM CaCl 2 , or 2 mM EGTA. Probing with an anti-human S100A1-specific antibody revealed 10-kDa (monomeric) and 20-kDa (dimeric) S100A1 species, which were pulled down by the GST-F 1 -ATPase ␣-and ␤-chain in the presence of 2 mM CaCl 2 and 0.2 mM CaCl 2 . GST alone (control) did not pull down S100A1. (B and C) Results of pull-down assays with GST-S100A1 and purified an elution profile that was clearly distinct from that obtained with 2 mM CaCl 2 . SDS-PAGE analysis of the first peak (fractions 36 to 40) revealed the five subunits of F 1 -ATPase but no monomeric or dimeric S100A1 protein. S100A1 eluted only in fractions corresponding to the second peak (fractions 49 to 53). This peak, which contains predominantly the free S100A1, was increased by approximately 150% compared to the corresponding peak obtained in the presence of 2 mM CaCl 2 ( Fig.  5A, peak II) . Together, the data indicate that S100A1 forms a complex with F 1 -ATPase in the presence of calcium at pH 7.4. To determine the functional effects resulting from the interaction of S100A1 with F 1 -ATPase, we measured the activity of isolated F 1 -ATPase incubated with S100A1 (Fig. 5C) . Accordingly, S100A1 caused an ϳ18% increase in F 1 -ATPase activity in the presence of 2 mM CaCl 2 and an ϳ28% increase in the presence of 0.2 mM CaCl 2 .
In conclusion, these studies substantiate the direct interaction of S100A1 with F 1 -ATPase and its effects on F 1 -ATPase activity.
S100A1 protein levels affect ATP synthase activity, ATP content, and Ca 2؉ transient amplitudes in cardiomyocytes. To address the functional significance of an S100A1-F 1 -ATPase interaction in cells, we examined the consequences of S100A1 knockdown on both ATP synthase activity and F 1 -ATPasemediated ATP production in cardiomyocytes.
To examine the relationship between S100A1 levels and ATP synthase activity, we used adult ventricular cardiomyocytes from WT and SKO (5) mice. The significantly higher conversion rate of NADH to NAD ϩ observed in WT than in SKO cardiomyocyte homogenates at 0.2 M and 0.2 mM free [Ca 2ϩ ] indicated a higher mitochondrial ATP synthase activity in WT cardiomyocytes (Fig. 6A) . Because cardiomyocyte homogenates were prepared in Ca 2ϩ -buffered solution, which prevented the loss of endogenous S100A1 protein in WT cardiomyocytes as confirmed by immunoblotting (data not shown), the higher ATP synthase activity could be attributed to S100A1. Consistently, the addition of recombinant S100A1 protein to SKO cardiomyocyte homogenates significantly increased mitochondrial ATP synthase activity at both 0.2 M and 0.2 mM free [Ca 2ϩ ]. To analyze the ATP content in cardiomyocytes expressing different S100A1 protein levels, NVCMs were transfected with S100A1 siRNA or scrambled control RNA. The efficient suppression of S100A1 protein by the specific siRNA in transfected NVCMs was confirmed by Western blotting (Fig. 6B) . Parallel NVCM cultures were lysed at 72 hours posttransfection, and subsequently, ATP levels were assayed by a luciferase-based luminometry reaction. As illustrated in Fig. 6B , knockdown of S100A1 expression in unstimulated NVCMs (S100A1 siRNA, basal conditions) caused ATP levels to decrease by an average of 48% compared to those in control cells transfected with scrambled siRNA or those in NT NVCMs. Consistent with the notion that S100A1 levels influence ATP production, overexpression of FIG. 5 . Results of gel filtration chromatography of the S100A1-F 1 -ATPase complex and determination of F 1 -ATPase activity. (A) Analysis of the S100A1-F 1 -ATPase complex in the presence of 2 mM CaCl 2 . The absorbance of the eluant was monitored at 280 nm. The elution profile shows two major peaks of different heights. Analysis of individual column fractions (x axis) on a 12 to 22% gradient SDS-PAGE gel reveals that peak I (fractions 36 to 42) contains the five subunits of F 1 -ATPase as well as S100A1 in the form of a dimer and a monomer (framed in black). Peak II (fractions 50 to 54) comprises the excess of recombinant S100A1. Only residual amounts of F 1 -ATPase subunits were detected in this peak. (B) In the presence of 2 mM EGTA, the elution profile of the S100A1-F 1 -ATPase complex displayed two symmetric peaks of comparable heights. The five subunits of F 1 -ATPase were eluted in peak I (column fractions 36 to 40), whereas S100A1 protein appeared only in peak II in the form of a monomer and a dimer (fractions 49 to 53). The S100A1 monomer is indicated by an arrowhead. (C) S100A1 increases F 1 -ATPase activity. S100A1 in NVCMs (AdS100A1) (Fig. 6C) increased ATP levels by 82% compared to those in control cells expressing endogenous S100A1 (Adcontrol and NT) (Fig. 6C) . Qualitatively similar results were obtained after the stimulation of cells with 1 M isoproterenol, a beta-adrenergic receptor agonist, or 10 mM CaCl 2 : S100A1-deficient NVCMs exhibited significantly reduced ATP levels (approximately 65% for isoproterenol-treated and 53% for CaCl 2 -treated knockdown NVCMs compared to the level for control cells), whereas overexpression of S100A1 consistently led to enhanced ATP levels (approximately 118% for isoproterenoltreated and 127% for CaCl 2 -treated AdS100A1 NVCMs compared to the level for control cells). Furthermore, compared to control or AdS100A1 cells, S100A1-deficient NVCMs were not able to respond with an adequate ATP increase after isoproterenol or CaCl 2 stimulation.
To examine the effects of reduced and increased levels of S100A1 on Ca 2ϩ cycling, we recorded Ca 2ϩ transients in NVCMs under basal and stimulated conditions (Fig. 6D) . In AdS100A1 cells overexpressing S100A1, the increased ATP content was accompanied by an increase in Ca 2ϩ transient amplitudes compared to what was observed for control cells (approximately 38% increase for basal, 35% for isoproterenoltreated, and 47% for CaCl 2 -treated AdS100A1 cells). Consistently, the suppression of S100A1 protein by S100A1 siRNA led to decreased Ca 2ϩ transient amplitudes (approximately 14% for basal, 30% for isoproterenol-treated, and 12% for CaCl 2 -treated AdS100A1 cells compared to the amplitude for control cells), concomitant with reduced ATP production. DISCUSSION S100A1 has recently been recognized to act as a regulator of Ca 2ϩ cycling and contractility in the heart (15, 20, 23) . However, efficient performance of the myocardium, in particular cardiac contractility, is based not only on Ca 2ϩ homeostasis but to a large extent also on energy metabolism (reviewed in references 6 and 10). Thus, the increase in cardiac contractility brought on by S100A1 overexpression strongly argued for a role for S100A1 in energy metabolism in addition to its role in Ca 2ϩ cycling. Indeed, we found that the ATP content measured in cardiomyocytes overexpressing S100A1 (AdS100A1) was 67% higher in resting AdS100A1 cells and even 110% higher in electrically stimulated AdS100A1 cells than in control cells. This ATP increase substantiates the notion that S100A1 is involved in the regulation of energy metabolism in cardiomyocytes.
Pull-down experiments with GST-S100A1 provided the first clues as to the molecular mechanism underlying the increase in ATP induced by S100A1. Interestingly, several mitochondrial proteins were pulled down by GST-S100A1, and virtually all of these potential S100A1 target proteins are involved in the cell's energy metabolism. In support of our findings, gel overlay experiments revealed glycogen phosphorylase and phosphoglucomutase, which, through their role in glycogenolysis, are also involved in energy production as potential target proteins of S100A1 (31) . In addition, S100A1 was shown to interact in a Ca 2ϩ -dependent manner with fructose-1,6-bisphosphate aldolase, thereby increasing its enzymatic activity (32) . Fructose-1,6-bisphosphate aldolase is a key regulator of glycolysis and is thus essential for energy production. Our data provide the first evidence that S100A1 interacts in a Ca 2ϩ -dependent manner with F 1 -ATPase in heart tissue. F 1 -ATPase is part of the F 1 F oATPase, which is responsible for ATP synthesis in the cell. Hence, it is tempting to speculate that the interaction of S100A1 with F 1 -ATPase is responsible for the increased ATP content in cardiomyocytes overexpressing S100A1. At this point, we cannot rule out that any of the other mitochondrial proteins pulled down by GST-S100A1, for example, the Ca 2ϩ -sensitive dehydrogenase isocitrate and the adenine nucleotide translocase, could also play a role in regulating the ATP content of the cell.
Because we were able to demonstrate a direct interaction of S100A1 with the ␣-and ␤-chain of F 1 -ATPase by reverse pull-down assays using the GST-F 1 -ATPase ␣-and ␤-chain as bait proteins for recombinant S100A1, we have focused our studies on the S100A1-F 1 -ATPase interaction. The specificity of this interaction was corroborated by the Ca 2ϩ dependence and pH sensitivity of S100A1 binding to the ␣-and ␤-chain of F 1 -ATPase. The most convincing piece of evidence that S100A1 biochemically interacts with F 1 -ATPase has been provided by the isolation of an S100A1-F 1 -ATPase complex by gel filtration chromatography.
For a physical interaction of S100A1 and F 1 -ATPase to occur in the cell, the spatial proximity of these proteins is required. While the localization of F 1 -ATPase in mitochondria has been known for quite some years (13) , there are only a limited number of studies that report a mitochondrial localization of S100A1. For example, electron microscopy studies have shown that S100A1 is present in the mitochondria of mouse slow-twitch fibers (8) as well as in mitochondria of the human heart (14) . Similarly, our data document the presence of S100A1 at the inner and outer mitochondrial membranes as well as in the matrix of rat heart mitochondria. Furthermore, double immunolabeling experiments from both confocal light and electron microscopy studies reveal that S100A1 and F 1 -ATPase indeed colocalize in mitochondria, indicating that a physical interaction between S100A1 and F 1 -ATPase is likely to occur in vivo.
A first indication of the functional significance of such an interaction has been reported by Simonian et al., who showed that S100A1 stimulated the ATPase activity in mitochondria isolated from gerbil brain (26) . The increased level of ATP we observed in cardiomyocytes that overexpress S100A1 extends the notion of a functional interaction between S100A1 and F 1 -ATPase. Moreover, the effect of S100A1 knockdown on the ATP level consolidates the association of S100A1 with mitochondrial ATP production. Further evidence is provided by the diminished mitochondrial ATPase activity observed in cardiomyocytes from S100A1 knockout mice. A direct indication of the influence of S100A1 on the function of F 1 -ATPase is provided by the determination of F 1 -ATPase activity. Indeed, the incubation of S100A1 with isolated F 1 -ATPase causes an 18% increase in F 1 -ATPase activity in the presence of 2 mM CaCl 2 and a 28% increase at 0.2 mM calcium. The direct impact of S100A1 protein on F 1 -ATPase activity is also demonstrated by restoring decreased mitochondrial ATP synthase activity in SKO cardiomyocytes through exogenous S100A1.
A potential interaction between the Ca 2ϩ -binding protein S100A1 and F 1 -ATPase raises the question of how energy production, as well as cardiac work, and Ca 2ϩ homeostasis are connected. In their recent work, Ventura-Clapier et al. have suggested that Ca 2ϩ is one of the main candidates for coupling energy metabolism and cardiac work (reviewed in reference 29). Furthermore, work by Territo et al. and Balaban has shown that cytosolic Ca 2ϩ plays an important role in the regulation of cardiac energy metabolism. Of particular interest is their finding that Ca 2ϩ activates several steps in oxidative phosphorylation, including F 1 F o -ATPase (27, 28 ; reviewed in reference 1). It has been proposed that Ca 2ϩ as an intermediary may concomitantly control both energy metabolism and cardiac work (28) . Because S100A1 not only improves cardiac Ca 2ϩ handling and heart muscle contractility (19) but also increases energy production, we speculate that the Ca 2ϩ sensor might be involved in coupling Ca 2ϩ cycling with Ca 2ϩ -dependent regulation of cardiac metabolism. This notion is supported by the finding that Ca 2ϩ transient amplitudes and ATP levels were concomitantly increased when S100A1 levels were raised, whereas knockdown of S100A1 reduced both ATP levels and Ca 2ϩ transient amplitudes. The important question of whether improved energy supply is crucial to S100A1 Ca 2ϩ -dependent inotropic actions in healthy and diseased myocardia will need to be addressed in future studies.
In conclusion, our data have unveiled a novel role for S100A1 in cardiac metabolism. Undoubtedly, more-detailed knowledge of the molecular interaction between F 1 -ATPase and S100A1 and also the other mitochondrial target proteins identified by pull-down assays is needed to more rationally understand the molecular mechanism by which S100A1 participates in cardiac energy metabolism. Elucidation of this molecular mechanism will ultimately provide insight into the failing heart where the cardiac pump is no longer able to meet the energy requirements of the body.
